Evidence map›Paper›PMID 33749263›Full record

ArticleJournal of proteome research2021

Discovery of Protein Modifications Using Differential Tandem Mass Spectrometry Proteomics.

Paolo Cifani, Zhi Li, Danmeng Luo, Mark Grivainis, Andrew M Intlekofer, David Fenyö, Alex Kentsis

Abstract read
In one paragraph

Article in Journal of proteome research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Itaconate modifications: Mechanisms and applications.Journal of intensive medicine · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Integrative Proteogenomics Using ProteomeGenerator2.Journal of proteome research · 2023
    Article
  10. Review
  11. Article
  12. Review
  13. The role of itaconate in host defense and inflammation.The Journal of clinical investigation · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Paolo CifaniMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, United States.ORCID 0000-0002-4403-1277
Zhi LiInstitute for Systems Genetics, NYU Grossman School of Medicine, New York, New York 10016, United States.
Danmeng LuoMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, United States.
Mark GrivainisInstitute for Systems Genetics, NYU Grossman School of Medicine, New York, New York 10016, United States.
Andrew M IntlekoferHuman Oncology & Pathogenesis Program and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, United States.
David FenyöInstitute for Systems Genetics, NYU Grossman School of Medicine, New York, New York 10016, United States.ORCID 0000-0001-5049-3825
Alex KentsisMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, United States.ORCID 0000-0002-8063-9191

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
ABERRANT SIGNALING IN ACUTE MYELOID LEUKEMIAR01CA204396 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KENTSIS, ALEX · 2016 to 2025
$5.2M
Metabolic control of normal and malignant hematopoiesisR37CA251543 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI INTLEKOFER, ANDREW MICHAEL · 2020 to 2025
$3.4M
Structure and function of genome plasticity in human cancerR01CA214812 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KENTSIS, ALEX · 2018 to 2022
$2.5M
Multi-dimensional targeted mass spectrometry technology for pathway-scale functional proteomicsR21CA235285 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KENTSIS, ALEX · 2019 to 2021
$625k
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA204396NCI NIH HHS R01 CA214812NCI NIH HHS R21 CA235285NCI NIH HHS R37 CA251543
6 · The paper itself

Abstract

Recent studies have revealed diverse amino acid, post-translational, and noncanonical modifications of proteins in diverse organisms and tissues. However, their unbiased detection and analysis remain hindered by technical limitations. Here, we present a spectral alignment method for the identification of protein modifications using high-resolution mass spectrometry proteomics. Termed SAMPEI for spectral alignment-based modified peptide identification, this open-source algorithm is designed for the discovery of functional protein and peptide signaling modifications, without prior knowledge of their identities. Using synthetic standards and controlled chemical labeling experiments, we demonstrate its high specificity and sensitivity for the discovery of substoichiometric protein modifications in complex cellular extracts. SAMPEI mapping of mouse macrophage differentiation revealed diverse post-translational protein modifications, including distinct forms of cysteine itaconatylation. SAMPEI's robust parametrization and versatility are expected to facilitate the discovery of biological modifications of diverse macromolecules. SAMPEI is implemented as a Python package and is available open-source from BioConda and GitHub (https://github.com/FenyoLab/SAMPEI).

Indexed as

ProteomicsTandem Mass SpectrometryAlgorithmsAnimalsMiceProtein Processing, Post-TranslationalSoftwarefunctional regulationitaconatemacrophagesmass spectrometrymetabolismpost-translational chemical modificationSAMPEIsignalingsoftwarespectral alignment

Identifiers

PMID33749263
PMCPMC8341206

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.